

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Over the past decade, the number of people living with sickle cell disease (SCD) worldwide has increased and reached an estimated 7.74 million in 2021. This increase has been accompanied by a rise in the disease burden related to SCD.¹ Sickle hemoglobin (HbS) polymerizes upon deoxygenation, initially reversible but becoming irreversible with repeated sickling, ultimately leading to rigidity, hemolysis and vaso-occlusion. This can lead to chronic hemolysis, vaso-occlusive events (VOE), and progressive multiorgan damage, and results in reduced life expectancy.²⁻⁵

Mitapivat, an oral allosteric activator of pyruvate kinase (PK) (a key enzyme in red blood cell [RBC] glycolysis that generates adenosine triphosphate [ATP] and reduces 2,3-diphosphoglycerate [2,3-DPG] levels) has recently emerged as a potential treatment. SCD is characterized by metabolic dysregulation, particularly within RBC. A hallmark of this disturbance is a reduced ATP/2,3-DPG ratio which contributes to impaired energy homeostasis and promotes Hb deoxygenation and sickling of RBC.⁶⁻⁸ Early clinical trials have demonstrated that mitapivat increases the ATP/2,3-DPG ratio, raises Hb, and decreases hemolysis in patients with SCD.⁹⁻¹¹

Of the organs affected by SCD, the kidneys are particularly susceptible to damage, often resulting in the early onset of progressive sickle cell nephropathy affecting up to 28-42% of the patients and considered to be the cause of death in 16.4% of patients with SCD. Sickle cell nephropathy can be assessed by evaluating renal markers such as Hb and nephrin, which indicate glomerular injury,^{12,13} β -N-acetylglucosaminidase (NAG), and kidney injury molecule-1 (KIM-1), which reflect proximal tubular dysfunction.¹⁴ These markers are elevated in patients with SCD before overt clinical sickle cell nephropathy becomes apparent.

We previously reported 1-year follow-up data from the investigator-initiated phase 2 ESTIMATE trial showing sustained hematologic improvement and reduced VOE frequency in 9 patients with SCD treated with mitapivat. Here, we provide the first 3-year results, extending observations into the prolonged fixed-dose extension period (PFDEP) and including exploratory renal outcomes.

The ESTIMATE study (EUCT 2024-515569-32-00) is an open-label, single-center phase 2 trial conducted at the University Medical Center Utrecht. Approval was obtained from the Medical Research Ethics Committee Utrecht, and all participants provided written informed consent. The study was conducted according to the principles of the Declaration of Helsinki, Good Clinical Practice, and GDPR regulations.

Eligible participants were aged ≥ 16 years with genotypes HbSS, HbS/ β^0 , or HbS/ β^+ , Hb levels 4.0-11.1 g/dL, and 1-10 VOE per year or another recent SCD-related complication. Patients were not receiving chronic transfusions. After an 8-week dose-finding phase (20-100 mg twice daily), responders entered a 1-year fixed-dose extension period (FDEP) followed by a 2-year PFDEP. Participants received dose adjustments as clinically indicated, with monitoring according to Good Clinical Practice and the principles of the Declaration of Helsinki. Normality was assessed visually (QQ-plots) for each variable and using the Shapiro-Wilk test; data are presented as mean \pm standard deviation (SD) or median (interquartile range) according to distribution. Non-parametric tests were applied when appropriate.

Ten patients received at least one dose of mitapivat; 9 completed the initial phase, and 7 entered the PFDEP. Two discontinued during the PFDEP (one self-discontinued after three months and one was withdrawn for non-compliance), leaving 5 patients who completed three years of therapy. Another 2 patients discontinued earlier, one because of pregnancy planning and one due to COVID-19-related pulmonary embolism during the first-year extension. At the time of this report, 5 participants continue long-term treatment in the ongoing extension phase. (See Table 1 for baseline characteristics.)

Over the full study duration, mitapivat demonstrated a favorable safety profile. All participants experienced at

Table 1. Baseline characteristics of patients with sickle cell disease treated with mitapivat.

	Dose-finding period N=10	Fixed-dose extension period N=9	Prolonged fixed-dose extension period N=7
Age, years, median (range)	26 (16-59)	30 (16-59)	24 (18-61)
Female, N (%)	6 (60)	5 (56)	4 (57)
SCD-genotype, N (%)			
HbSS	8 (80)	7 (78)	3 (60)
HbS/ β^0 -thalassemia	1 (10)	1 (11)	1 (14)
HbS/ β^+ -thalassemia	1 (10)	1 (11)	1 (14)
Concomitant hydroxyurea therapy, N (%)	6 (60)	6 (67)	4 (57)

N: number; SCD: sickle cell disease.

least one treatment-emergent adverse event (TEAE), the vast majority being mild (grade 1) and transient. During the 2-year PFDEP, 22 TEAE occurred across 7 participants; 86% were grade 1, 4.5% grade 2, and 9.1% grade 3. The most frequent findings were asymptomatic alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations, each observed in 3 participants. The mean transaminase values remained within normal limits, without any trend toward cumulative hepatotoxicity. No dose reductions or permanent discontinuations were required because of liver enzyme changes, and all elevations resolved spontaneously. Two grade 3 events were reported: infectious lumbosacral radiculitis and pneumonia with small subsegmental pulmonary emboli, both in participants with recent non-compliance. No grade 4 or 5 events occurred during the PFDEP, and no patient discontinued treatment for safety reasons. (Details are shown in Table 2.) The single fatal event in the entire study, a massive COVID-19-related pulmonary embolism, occurred during the first-year extension while the participant was on mitapivat; the investigator concluded that this was unrelated to treatment.

Efficacy outcomes remained consistent with earlier findings. Across all treated participants, mean Hb increased from 8.8 ± 1.8 to 9.6 ± 1.7 g/dL after three years ($P=0.01$), while absolute reticulocyte count decreased from 235 ± 88 to $170 \pm 81 \times 10^9/L$ ($P<0.01$). Total bilirubin declined from 2.6 ± 1.3 to 1.4 ± 0.7 mg/dL ($P=0.02$). Lactate dehydrogenase (LDH) decreased numerically (500 to 421 U/L; $P=0.08$), but this was not significant. These sustained hematologic effects mirror

the 1-year data and support a long-term disease-modifying impact of PK activation. (See *Online Supplementary Figure S1* for mean laboratory results over time.)

The annualized VOE rate fell from 1.33 ± 1.32 events per year before enrollment to 0.60 ± 0.78 during the 1-year FDEP and 0.14 ± 0.24 during the PFDEP ($P=0.07$). The 2 VOE recorded in the PFDEP both occurred in non-compliant participants, suggesting that treatment adherence critically influences efficacy. Likewise, SCD-related hospitalization days declined from 5.5 ± 6.6 to 2.1 ± 2.3 days per year ($P=0.25$). Intention to treat laboratory and clinical endpoints are shown in Table 3. Although, owing to the small sample size, this was not statistically significant, these reductions are clinically relevant and aligned with the improvements in hemolysis and Hb. The reduction in VOE frequency may in part reflect closer clinical monitoring during the study; however, events were prospectively captured and independently adjudicated. Exploratory renal analyses were performed on 5 patients with paired urine samples collected at baseline and after one or two years of therapy. Urinary albumin-to-creatinine ratio (UACR) was assessed in a single spot urine sample at baseline and follow-up. Renal markers were normalized to urinary creatinine. Glomerular injury markers showed marked proportional declines: nephrin / creatinine decreased by 50.7%, and urinary Hb-to-creatinine ratio by 99.8%. In contrast, the tubular marker KIM-1/creatinine declined by 92.0%, while β -N-acetylglucosaminidase (NAG) / creatinine increased by 40.2%. These opposite trends in glomerular and tubular indicators may reflect distinct

Table 2. Treatment emergent adverse events of patients with sickle cell disease treated with mitapivat (N=7). Safety analysis set of prolonged fixed-dose extension period.

AE, N (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Total	19 (86.4)	1 (4.5)	2 (9.1)	0	0
Seborrheic keratosis	1 (4.5)	-	-	-	-
Aspartate aminotransferase increased	4 (18.2)	-	-	-	-
Alanine aminotransferase increased	5 (22.7)	-	-	-	-
Thrombocytosis	1 (4.5)	-	-	-	-
Conjunctivitis	1 (4.5)	-	-	-	-
Headache	2 (9.1)	-	-	-	-
Pain in hip joint	1 (4.5)	-	-	-	-
Gastro-intestinal discomfort	1 (4.5)	-	-	-	-
Palpitations	1 (4.5)	-	-	-	-
Insomnia	1 (4.5)	-	-	-	-
Nausea and vomitus	1 (4.5)	-	-	-	-
Dyspnea	-	1 (4.5)	-	-	-
Lumbosacral radiculitis	-	-	1 (4.5)	-	-
Pneumonia with pulmonary emboli	-	-	1 (4.5)	-	-

Patients with multiple adverse events (AE) within a preferred term were counted only once in that preferred term. For participants with multiple occurrences of an AE, the AE with the worst Common Terminology Criteria for Adverse Events grade is included in the summary.

pathophysiological responses to improved erythrocyte energetics. UACR categories remained stable in all 5 subjects, with Subjects 1 and 3 remaining in the moderately elevated range and Subjects 2, 9, and 10 remaining within the normoalbuminuria range. For eGFR, all patients remained >90 mL/min/1.73 m² and none showed a decline below this threshold at last follow-up, suggesting absence of progressive renal impairment during treatment. The observed nephrin and hemoglobinuria declines, though underpowered for statistical testing, are consistent with reduced glomerular stress and deserve confirmation in larger cohorts. (See *Online Supplementary Figure S2* for renal outcomes)

Other exploratory safety endpoints included bone mineral density (BMD) and sex hormones, measured annually by DEXA and immunoassay. No significant changes were seen in testosterone, estrone, or estradiol levels over three years, and BMD scores remained stable, with a slight upward trend in hip Z-scores. These findings suggest that long-term PK activation does not adversely affect bone or endocrine homeostasis.

The per-protocol analysis, limited to patients with ≥80% adherence, confirmed sustained hematologic benefit, particularly in Hb. In the strict per-protocol subset excluding non-compliant participants, both the annualized VOE rate and hospitalization days were zero during the PFDEP. The

concordance between biochemical and clinical improvements further underscores the importance of continuous dosing for optimal response.

Overall, these data show that mitapivat is well tolerated and produces durable improvement in hemolysis and anemia in SCD over three years of treatment. The safety profile remained stable without new or cumulative toxicity, and the only severe events were unrelated or occurred in non-adherent participants. The consistent hematologic gains, combined with a striking reduction in VOE and hospitalization days, highlight mitapivat's potential as a long-term disease-modifying therapy targeting RBC metabolism. This study also contributes novel exploratory insights into renal outcomes in SCD. While limited by small sample size, the reduction in glomerular injury markers such as nephrin/creatinine and hemoglobinuria may indicate early renal protection through PK activation. Preclinical studies have shown that PKM2 activation can reduce fibrosis and iron deposition in murine SCD nephropathy, supporting the plausibility of this mechanism. Although tubular markers showed mixed trends, the overall pattern does not suggest worsening renal injury.

We acknowledge the primary limitation of this study, the small cohort inherent to a first-in-class, investigator-initiated trial in a rare disease setting. The resulting lack of statistical power restricts inferential conclusions. Nevertheless,

Table 3. Intention to treat analysis.

Parameter	Baseline N=9	Mean of FDEP N=9	Mean of PFDEP N=7	P (baseline vs. PFDEP) N=7
Hb level and markers of hemolysis				
Hb, g/dL	8.8 (1.8)	9.9 (1.8)	9.6 (1.7)	0.01
ARC, 10 ⁹ /L	235 (88)	156 (50)	170 (81)	<0.01
Total bilirubin, mg/dL	2.6 (1.3)	1.4 (0.7)	1.4 (0.7)	0.02
LDH, U/L	500 (307)	398 (216)	421 (204)	0.08
Biochemical parameters				
AST, U/L	44 (31)	47 (30)	36 (27)	0.16
ALT, U/L	25 (13)	36 (21)	26 (13)	0.11
Surrogate markers				
Erythropoietin IU/L*	181 (240)	156 (226)	164 (166)	0.81
NT-proBNP, pg/mL*	342 (792)	267 (524)	79 (72)	1.00
CRP, mg/L	5.6 (5.1)	6.9 (6.7)	8.7 (3.3)	0.22
LDH/HbCO ratio	3,838 (3,554)	4,640 (2,420)	3,907 (2,689)	0.84
D-dimer mg/L	2.8 (3.1)	4.1 (7.0)	1.6 (1.5)	1.00
VWF antigen, %	188 (73)	160 (49)	189 (71)	0.85
ACR mg/mmol*	133 (214)	170 (327)	49 (67)	0.84
Markers of SCD-related complications				
Annualized VOE rate	1.33 (1.32)	0.60 (0.78)	0.14 (0.24)	0.07
Annualized SCD-related hospital admission days*	5.5 (6.6)	4.1 (5.6)	2.1 (3.8)	0.25

Data are presented as mean (standard deviation). P values are derived from paired sample t tests or Wilcoxon signed-rank tests, based on participants with complete paired measurements (N=7), comparing baseline values with Prolonged Fixed Dose Extension Period (PFDEP) values. *Non-normally distributed and therefore analyzed with the Wilcoxon signed-rank test. ACR: albumin-to-creatinine ratio; ALT: alanine transaminase; ARC: absolute reticulocyte count; AST: aspartate aminotransferase; CRP: C-reactive protein; Hb: hemoglobin; LDH: lactate dehydrogenase; LDH/HbCO: lactate dehydrogenase to carboxyhemoglobin ratio; NT-proBNP: N-terminal pro-brain natriuretic peptide; SCD: sickle cell disease; VOE: vaso-occlusive event; VWF: von Willebrand factor.

the longitudinal follow-up of nearly 1,000 patient-weeks provides valuable real-world insight into chronic PK activation. Given the consistency of effects across all treated participants and the alignment with earlier phase 1-2 findings, these results are meaningful for clinical translation. In conclusion, three years of mitapivat therapy in patients with SCD demonstrated sustained hematologic and clinical benefits, a reassuring long-term safety profile, and preliminary evidence suggesting renal benefit. These findings strengthen the rationale for larger, controlled trials assessing PK activation as a metabolic disease-modifying strategy in sickle cell disease.

Authors

Geoffrey Z.L. Kuppens,¹ Maria Armila D. Ruiz,² Myrthe J. van Dijk,^{1,3} Minke A. E. Rab,^{3,4} Cleo Derichs,¹ Joline Saes,¹ Anita W. Rijnveld,⁴ Marjon H. Cnossen,⁵ Erfan Nur,^{6,7} Bart J. Biemond,⁶ Marije Bartels,¹ Santosh L. Saraf² and Eduard J. van Beers¹

¹Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; ²Division of Hematology/Oncology, University of Illinois Hospital & Health Sciences System, Chicago, IL, USA; ³Department of Central Diagnostic Laboratory - Research, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; ⁴Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; ⁵Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital University Medical Center Rotterdam, Rotterdam, the Netherlands; ⁶Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands and ⁷Department of Blood Cell Research, Sanquin Research, Amsterdam, the Netherlands

Correspondence:

E.J. VAN BEERS - e.j.vanbeers-3@umcutrecht.nl

<https://doi.org/10.3324/haematol.2025.289105>

Received: September 2, 2025.

Accepted: February 19, 2026.

Early view: February 26, 2026.

Published under a CC BY license 

Disclosures

MAER is consultant for Agios Pharmaceuticals and RR Mechatronics, and has received research funding from Pfizer, RR Mechatronics and

Agios Pharmaceuticals, receives research funding from Axcella Therapeutics and Pfizer, and receives research funding from and is a consultant for Agios Pharmaceuticals Inc.; SLS receives research funding from Pfizer, Novartis and Novo Nordisk, and has served as a consultant for Agios Pharmaceuticals, BEAM therapeutics, Merck, Novo Nordisk, Novartis, Pfizer, CSL Behring, Chiesi and Fulcrum; EJvB receives research funding from and is a consultant for Agios Pharmaceuticals Inc., and is a consultant for Pfizer; MHC has received investigator-initiated research and travel grants as well as speaker fees over the years from the Netherlands Organization for Scientific Research and Netherlands National Research Agenda, the Netherlands Organization for Health Research and Development (ZonMw), the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche and Nordic Pharma, and has served as a steering board member for Roche, Bayer and Novartis; EN receives research funding from Novartis and has participated in speakers bureau for VERTEX; BJB receives research funding from Pfizer, BMS, Novartis and Novo Nordisk, has participated in the advisory boards of Pfizer, BMS and Celgene, and received honoraria for lectures or podcasts from Novo Nordisk and Sanofi. All the other authors have no conflicts of interest to disclose.

Contributions

EJvB directed and designed the research, developed methodology, recruited patients and/or provided patient data, performed the research, acquired, analyzed and interpreted data, and reviewed and revised the manuscript; MJvD designed the research and developed methodology, recruited patients and/or provided patient data, performed the research and acquired data; MAER designed the research and developed methodology; GZLK recruited patients and/or provided patient data, performed the research, acquired, analyzed and interpreted data, and wrote the manuscript; CD and JS recruited patients and/or provided patient data, performed the research and acquired data; AWR, MHC, EN and BJB recruited patients and/or provided patient data; MADR advised on and analyzed the renal samples; MB recruited patients and/or provided patient data, and reviewed and revised the manuscript; SLS advised on and analyzed the renal samples, and reviewed and revised the manuscript. All authors reviewed the manuscript critically and approved the final version of the manuscript for publication.

Data-sharing statement

For original data and protocol, please contact the corresponding author (E.J.vanBeers-3@umcutrecht.nl). Data will be shared as allowed by GDPR and EU privacy laws, depending on location of the new data controller/processor and applicable national law.

References

1. GBD 2021 Sickle Cell Disease Collaborators. Global, regional,

and national prevalence and mortality burden of sickle cell

- disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. *Lancet Haematol.* 2023;10(8):e585-e599.
2. Rees, DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet.* 2010;376(9757):2018-2031.
 3. Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. *JAMA Netw Open.* 2019;2(11):e1915374.
 4. Osunkwo I, Andemariam B, Minniti CP, et al. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY). *Am J Hematol.* 2021;96(4):404-417.
 5. Jiao B, Johnson KM, Ramsey SD, et al. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. *Blood Adv.* 2023;7(13):3276-3283.
 6. Adebisi MG, Manalo JM, Xia Y. Metabolomic and molecular insights into sickle cell disease and innovative therapies. *Blood Adv.* 2019;3(8):1347-1355.
 7. Darghouth D, Koehl B, Madalinski G, et al. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. *Blood.* 2011;117(6):e57-e66.
 8. Rab MAE, Bos J, van Oirschot BA, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. *Blood.* 2021;137(21):2997-3001.
 9. van Dijk MJ, Rab MAE, van Oirschot BA, et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. *Am J Hematol.* 2022;97(7):E226-E229.
 10. van Dijk MJ, Rab MAE, van Oirschot BA, et al. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. *Blood Adv.* 2023;7(24):7539-7550.
 11. Xu JZ, Conrey A, Frey I, et al. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. *Blood.* 2022;140(19):2053-2062.
 12. Saraf SL, Zhang X, Kaniyas T, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. *Br J Haematol.* 2014;164(5):729-739.
 13. Heimlich JB, Chipoka G, Elsherif L, et al. Nephtrin as a biomarker of sickle cell glomerulopathy in Malawi. *Pediatr Blood Cancer.* 2018;65(6):e26993.
 14. Sundaram N, Bennett M, Wilhelm J, et al. Biomarkers for early detection of sickle nephropathy. *Am J Hematol.* 2011;86(7):559-566.